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Abstract Choice of therapy for breast cancer relies on
human epidermal growth factor receptor-2 (HER2) and
estrogen receptor a (ER) status. Before randomization in
the phase III Adjuvant Lapatinib and/or Trastuzumab
Treatment Optimisation (ALTTO) trial for HER2-positive
disease, HER2 and ER were centrally reviewed by Mayo
Clinic (Rochester, MN, and Scottsdale, AZ) for North
America and by the European Institute of Oncology (IEO;
Milan, Italy) for the rest of world (except China). Discor-
dance rates (local vs. central review) differed between
Mayo and IEO. Among locally HER2-positive cases,
5.8 % (Mayo) and 14.5 % (IEO) were centrally HER2
negative. Among locally ER-positive cases, 16.2 %
(Mayo) and 4.2 % (IEO) were centrally ER-negative.
Among locally ER-negative cases, 3.4 % (Mayo) and
21.4 % (IEO) were centrally ER-positive. We, therefore,
performed a ring study to identify features contributing to
these differing discordance rates. Mayo and IEO exchan-
ged slides for 25 HER2 and 35 ER locally/centrally dis-
cordant cases. Both laboratories performed IHC and FISH
for HER2 using the HercepTest and PathVysion HER2
DNA probe kit/HER2/centromere 17 probe mixture. IHC
for ER was tested centrally using the monoclonal ER 1D5
antibody (Mayo) or the DAKO cocktail of ER 1D5 and
2.123 antibodies (IEO). Mayo and IEO confirmed the
central HER2-negative result in 100 % of 25 cases. Mayo
and IEO confirmed the central ER result in 29 (85 %) of 34
evaluable cases. The five Mayo-negative/IEO-positive
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cases were ER-positive when retested at Mayo using the
DAKO ER cocktail. In this ring study, ALTTO ineligibility
did not change when HER2 testing was performed by
either IEO or Mayo central laboratories. However, a dual
antibody ER assay had fewer false-negative test results
than an assay with a single antibody, and there was more
discordance between the two ER reagents than has been
previously reported. Using even slightly different assay
methods yielded different results, even between experi-
enced central laboratories.
Keywords Breast cancer  Estrogen receptor testing 
HER2 testing  Central laboratory review  Local versus
central laboratory concordance
Background
Adjuvant Lapatinib and/or Trastuzumab Treatment
Optimisation (ALTTO) is a phase III randomized inter-
national clinical trial conducted by the Breast Interna-
tional Group (BIG) and the North American Breast
Cancer Groups [NABCG: lead group, North Central
Cancer Treatment Group (NCCTG, now part of the
Alliance)]. ALTTO evaluates the role of adjuvant la-
patinib alone, or in combination or sequence with trast-
uzumab compared with trastuzumab alone for the
adjuvant treatment of patients with early human epider-
mal growth factor receptor-2 (HER2)-positive breast
cancer. Trial overview and further details can be found
in the trial Web site (http://alttotrials.com). Between
April 2007 and July 2011, 8,381 patients were enrolled
in ALTTO.
One of the key features of the trial is that patients
with disease classified as HER2 positive or HER2
equivocal by local laboratories were eligible for ran-
domization only after HER2-positive status was con-
firmed by a central laboratory. Mayo Clinic (Mayo:
Rochester, Minnesota; Scottsdale, Arizona, Drs. Robert
Jenkins, Ann McCullough, Wilma Lingle) was responsi-
ble for confirmatory testing for North American patients
enrolled through US NCI sponsorship; European Institute
of Oncology (IEO: Milan, Italy, Dr. Giuseppe Viale) was
responsible for confirmatory testing for patients from the
rest of the world (except China that used a third central
laboratory).
There is an increasing recognition that HER2-positive
disease that is also steroid hormone receptor positive has a
different natural history and requires different adjuvant
therapy than HER2-positive disease that does not express
either estrogen receptor a (ER) or progesterone receptor
(PR) [1], specifically, antiestrogens after the completion
of chemotherapy. The lack of local/central concordance in
pathological reading of estrogen and progesterone recep-
tor status in tumor specimens has been documented [2].
Therefore, central laboratory determination of ER and PR
status was also initiated in ALTTO, and the stratification
of patients in the randomization was according to cen-
trally determined hormone receptor status of the primary
tumor.
In this manuscript, we present results of a ring study in
which a small number of cases were exchanged between
Mayo and IEO for assessment of HER2 or ER status in
order to understand the similarities or differences in results
obtained between the two central confirming laboratories.
PR status was not considered in this ring study.
Motivation for the ring study
The ALTTO Steering Committee annually reviewed data
regarding eligibility failures (defined as locally HER2
positive, but HER2 negative at central review) as well as
discrepancies between local and central determinations of
ER status. In 2009, it was recognized that very few of the
locally HER2-positive cases referred to Mayo were found
to be ineligible (5.8 %), while 14.5 % of the HER2-posi-
tive cases referred to IEO were defined centrally as HER2
negative (Table 1). In addition, differences between central
laboratories were seen with respect to ‘false-positive’ and
‘false-negative’ ER rates. The percent of cases defined as
ER-positive locally but ER-negative on central review (i.e.,
false positive) was 16.2 % at Mayo compared with 4.2 %
at IEO (Table 2). The percent of cases defined as ER-
negative locally but with at least 1 % of cells staining
positive for ER centrally (i.e., false negative) was 3.4 % at
Mayo compared with 21.4 % at IEO (Table 2). ALTTO
recruitment was completed in July 2011, and the final
concordance figures between local and central laboratory
determinations for HER2 and ER are shown in Supple-
mentary Appendix C.
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Methods
Ring study design
This ring study involved an exchange of slides between
Mayo and IEO. There were three phases, which were
launched sequentially based on results of the preceding
phases. The statisticians (ACD and RDG) selected the
cases per criteria described below. All evaluations were
conducted with the pathologists blinded to the evaluations
from the other laboratory, and the results were combined
by the statisticians for analysis. Definitions of testing
results followed published ASCO/CAP guidelines [3, 4], as
summarized in Supplementary Appendix A.
Phase 1 was motivated by the false-positive and false-
negative rates (Tables 1, 2) and involved exchange of
material as follows: IEO submitted to Mayo for retesting
20 HER2 false-positive cases, 5 ER false-positive cases,
and 5 ER false-negative cases; Mayo submitted to IEO for
retesting 5 HER2 false-positive cases, 20 ER false-positive
cases, and 5 ER false-negative cases. False positive was
defined as locally positive/centrally negative, while false
negative was defined as locally negative/centrally positive.
Thus, for studying HER2 concordance, 25 cases with
central HER2-negative status were exchanged, 20 from
IEO, and 5 from Mayo. Cases that were centrally HER2
positive were not included in phase 1 of the ring study. For
studying ER status, 25 centrally ER-negative cases (5 from
IEO and 20 from Mayo) and 10 centrally ER-positive (5
from each laboratory) cases were exchanged.
Phase 2 was initiated when IEO identified 5 of the 20
Mayo ER-negative cases from phase 1 as ER positive. The
Mayo laboratory evaluated eleven of the previously tested
cases using the dual ER antibody method used at the IEO
site. The 5 discordant cases and 6 non-discordant cases
were retested to maintain blinding of the pathologists.
Phase 3 was initiated when it was recognized that the
HER2 testing in the phase 1 plan included only cases that
were locally HER2 positive, but centrally HER2 negative.
The additional question was whether IEO central review
would confirm HER2 positivity for cases that were locally
IHC equivocal (by local laboratory criteria) and centrally
HER2 positive at Mayo. Therefore, in phase 3, 23 addi-
tional cases not previously involved in the ring study and
with local IHC equivocal results for HER2 were sent from
Mayo to IEO for HER2 retesting: 10 were Mayo IHC
positive and FISH positive (ratio[2.2), 5 were Mayo IHC
equivocal and FISH positive, 5 were Mayo IHC equivocal
and FISH negative (ratio \1.8), and 3 were Mayo IHC
negative and FISH negative.
HER2 and ER testing methods
The various procedures used by the Mayo and the IEO
laboratories are described in Supplementary Appendix B.
In the central laboratories, HER2 IHC was tested using the
HercepTest kit (Dako, Carpinteria, CA), and HER2 FISH
was tested using the PathVysion HER2 DNA probe kit/
HER2/CEP17 probe mixture (Abbott Molecular, Des
Plaines, IL). HER2 positivity was defined according to the
2007 ASCO/CAP guidelines (IHC positive: 3? complete
membrane staining in [30 % of invasive cells; FISH
positive: HER2/CEP17 ratio [2.2) [3].
IEO and Mayo performed IHC for ER each according to
their own methods, previously used in large multicenter
trials and each recommended by ASCO/CAP ER/PR
Table 1 Concordance between local and central HER2 status/com-
bined IHC and FISH methods (as of December 2009)
Local HER2 status Central laboratory
Mayo IEO
Local HER2 positive
Total cases 412 8,037
Centrally eligible 388 6,871
Centrally not eligible 24 (5.8 %) 1,166 (14.5 %)
Local HER2 equivocal
Total cases 13 1,041
Centrally eligible 6 647
Centrally not eligible 7 (53.8 %) 394 (37.8 %)
A case was centrally eligible (HER? positive) if either central IHC or
FISH was positive; positivity of one test was sufficient. Both IHC and
FISH were performed on all carcinomas eligible for enrollment in the
trial
HER2 human epidermal growth factor receptor 2, IHC immunohist-
ocytochemical, FISH fluorescent in situ hybridization, Mayo Mayo
Clinic central laboratory, IEO European Institute of Oncology central
laboratory
Table 2 Concordance between local and central ER status (as of
December 2009)
Local ER status Central laboratory
Mayo IEO
Local ER positive
Total cases 272 4,899
Positive C10 % 224 4,590
Positive C1 % and \10 % 4 101
Negative 44 (16.2 %) 208 (4.2 %)
Local ER negative
Total cases 147 4,122
Positive C10 % 5 (3.4 %) 665 (16.1 %)
Positive C1 % and \10 % 0 (0.0 %) 217 (5.3 %)
Negative 142 3,240
ER estrogen receptor, Mayo Mayo Clinic central laboratory, IEO
European Institute of Oncology central laboratory
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testing guidelines. IEO used a dual antibody (Dako cocktail
of ER 1D5 and 2.123 monoclonal antibodies), while Mayo
used a single antibody (Dako ER 1D5 monoclonal anti-
body). ER status was defined as positive if C1 % cells
stained positively versus \1 % for negative.
Statistical analysis
All statistical analyses were descriptive consisting pri-
marily of listings of results for the cases, as well as relative
frequencies with exact binomial confidence intervals. The
phase 1 sample size to retest 30 cases per laboratory was
selected primarily to control costs for this underfunded
investigation. In phase 1, the selection of more cases in
some categories—20 HER2 false positive from IEO to
Mayo and 20 ER false positive from Mayo to IEO—was
based on the two primary goals to be evaluated. With 20
cases in a group, the 95 % exact binomial confidence
interval would be 83–100 % if all 20 were confirmed, and
51–91 % if 15 of the 20 were confirmed (point estimate
75 %).
Results
Phase 1: HER2 central laboratory concordance
The results of the HER2 testing in phase 1 are shown in
Supplementary Appendix D. Both central laboratories
identified ALTTO ineligibility (HER2 negative) in each of
the 25 cases exchanged. There was a slight tendency for
Mayo evaluations to be in the equivocal category (rather
than in the negative category) for both IHC (7 Mayo, 1
IEO) and FISH (3 Mayo, 0 IEO) determinations, but this
did not impact the HER2-negative ineligibility determina-
tion in any case.
Phase 1: ER central laboratory concordance
By contrast, discordance was observed with respect to ER
determinations (Table 3). Five of 34 cases with ER deter-
mination in both laboratories [15 %; 95 % confidence
interval (CI), 5–31 %] were discordant. Five of the 20
Mayo ER-negative cases sent to IEO (25 %; 95 % CI
9–49 %) were determined to be ER positive at IEO.
Assessments were concordant for all 5 IEO ER-negative
cases, for all 5 IEO ER-positive cases, and for all 5 Mayo
ER-positive cases.
Phase 2: ER retesting at Mayo
When the 11 cases in phase 2 were retested at Mayo using
the dual antibody, all 11 gave results that were concordant
with the IEO central laboratory determination (Table 3).
Figure 1 shows the difference in staining for ER in two
carcinomas when the dual antibody is used as compared
with the single antibody.
Phase 3: HER2 retesting at IEO
Table 4 shows the results of the review of the 23 cases
included in phase 3. All 23 cases had equivocal local HER2
IHC results. Five of the 15 cases (33 %; 95 % CI 12–62 %)
that were HER2 positive at Mayo central review did not
reach the threshold of positivity by the IEO review. By
contrast, only 1 of the 8 cases (12 %; 95 % CI 0–53 %)
that was HER2 negative at Mayo was HER2 positive at
IEO (Table 4). A clear tendency was observed for the
ratios above 2 to be higher for the Mayo central review
compared with the IEO central review (Fig. 2). This ten-
dency is due to the fact that the Mayo central review
counted nuclei with fewer than 2 green signals, while IEO
central review did not.
Discussion
This ring study clearly established diversity between cen-
tral laboratory results due to both technical issues in
immunohistochemical testing and interpretation issues in
Table 3 Concordance in ER status between central laboratories—35
cases included in the original set (phase 1) and 11 cases repeated at
Mayo using dual antibody (phase 2)
ER IHC original seta Mayo (single antibody)
ER negative ER positive
IEO (dual antibody)
ER negative 19 –
ER positive 5 10
Not evaluable 1 –
ER IHC (repeated set)b Mayo (dual antibody)
ER negative ER positive
IEO (dual antibody)
ER negative 3 –
ER positive – 8
ER estrogen receptor, IHC immunohistochemical, Mayo Mayo Clinic
central laboratory, IEO European Institute of Oncology central
laboratory
a Includes 35 cases: 5 ER false positive (locally positive/centrally
negative) and 5 ER false negative (locally negative/centrally positive)
submitted from IEO to Mayo; and 20 ER false positive and 5 ER false
negative submitted from Mayo to IEO
b Includes 11 cases previously tested from Mayo (6 of the 20 ER false
positive and all 5 of the ER false negative)
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FISH testing. Epitope mapping of the two antibodies con-
tained in the dual ER cocktail used at IEO indicates
binding to amino acid sequence 15–23 of the N-terminus
for clone ER-2-123 (region A), and binding to amino acid
sequence 127–130 for clone 1D5 (region B) [5]. The
different rates of false-negative determination of ER we
postulate are due to the use of dual ER antibody with a
second epitope binding site in IEO compared with the older
single epitope ER ID5 reference antibody used at Mayo. In
phase 2, the use of dual antibody on cases reassessed at
Fig. 1 Representative ER IHC staining in two separate carcinomas
(910). Sections A and C are each from carcinoma #1; B and D are
each from carcinoma #2. All stains were performed at Mayo. ER IHC
staining using single ER antibody (1D5) is depicted in A, B. ER IHC
staining using the dual ER antibody cocktail (1D5/2, 123) is depicted
in C, D. Each carcinoma shows negative staining with single ER
antibody (A, B) and positive staining by dual antibody cocktail (C, D)
Table 4 23 cases with locally
equivocal IHC for
determination of HER2
positivity (bold values indicate
discordance between central
laboratories)
IHC immunohistochemical,
HER2 human epidermal growth
factor receptor 2, FISH
fluorescent in situ hybridization,
Mayo Mayo Clinic central
laboratory, IEO European
Institute of Oncology central
laboratory, neg negative, equ
equivocal, pos positive
IEO central Mayo central Total
HER2 negative HER2 positive
IHC neg/
FISH neg
IHC equ/
FISH neg
IHC equ/
FISH equ
IHC equ/
FISH pos
IHC pos/
FISH pos
HER2 negative
IHC neg/FISH neg 3 3 – 1 – 7
IHC equ/FISH neg – 1 – 1 – 2
IHC equ/FISH equ – – – 2 1 3
HER2 positive
IHC equ/FISH pos – 1 – 1 3 5
IHC pos/FISH pos – – – – 6 6
Total 3 5 0 5 10 23
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Mayo found ER expression levels concordant between the
two laboratories. Standardized assays using the same
reagents tend to increase concordance between the labo-
ratories; the same method on the same tissue yielded the
same result in ER IHC testing. ASCO/CAP guidelines for
ER testing identified four well-validated antibodies for ER
immunohistochemical detection on the basis of outcomes
in estrogen receptor modulating therapeutic trials [4].
These antibodies were 6F11, 1D5 (used at Mayo), SP1, and
the dual 2.123 ? 1D5 (used at IEO). We found more dis-
cordance between these clinically validated ER antibodies
than previously reported in a single laboratory study
demonstrating 99 % concordance between the two anti-
bodies [6].
Interpretation appears to play a role in the assessment of
HER2 positivity, affecting both IHC and FISH results. The
higher agreement regarding HER2 positivity between Mayo
and local US sites compared with IEO and local rest-of-
world sites might be due in part to the differences between
central laboratories highlighted in phase 3 of this ring study.
While the phase 1 initial part of the ring study provided
100 % concordance between central laboratories in cases
that were clearly not eligible, the phase 3 part involving 23
cases with equivocal local HER2 IHC results revealed more
positive FISH calls at Mayo compared with IEO. Similar low
discordance was found in another HER2 international ring
study utilizing predominantly equivocal immunohisto-
chemical and borderline FISH cases [7]. There are several
reasons for the discordance in phase 3. First, some
discordance in FISH results between laboratories is likely
due to the way the FISH-amplified signals are counted. When
clouds of amplification (strongly clustered fluorescence
partially obscuring individual nuclear signals) are seen, the
Mayo pathologists assign a copy number of 20 based on the
strong belief that one cannot count the signals in the cloud.
Others, however, try to estimate the number of HER2 sig-
nals, and these estimates are always less than 20. Second,
there are also differences in how the green (control CEP17)
signals are counted. Some laboratories (such as the central
IEO laboratory) only enumerate nuclei with 2 or more green
signals. Other laboratories count nuclei with any numbers of
green signals. The latter method will also inflate the
HER2:CEP17 ratio. Third, phase 3 was focused on IHC
equivocal cases. A large proportion of these cases had
duplication or low-level amplification (e.g., 3–6 HER2 sig-
nals). The HER2:CEP17 ratios for such cases usually range
from 1.3 to 3.0, so some laboratories may observe ratios
slightly over and others slightly under 2.0 (or 2.2). Fourth,
two of the 23 cases in phase 3 of the ring study contained
clear heterogeneous HER2 amplification. However, the
overall ratio was less than 2, and the fraction of amplified
cells was less than 50 %. Accordingly, the final classification
of these tumors was not amplified. In light of the new ASCO/
CAP recommendations, these tumors would qualify as
amplified if the fraction of amplified cells is higher than
10 %. Fifth, two cases were reflexed (at Mayo) to a 17 p-arm
control probe (D17S122) because CEP17 exhibited frequent
aneusomy, and this reflex increased the ratio.
It is not possible to know which central laboratory
determination of HER2 status or ER status was biologically
correct in terms of distinguishing patients who do or do not
benefit from HER2-targeted or endocrine therapies,
respectively. Determinations of trial eligibility based on
interpretation of FISH testing in HER2 immunohisto-
chemically equivocal patients differed somewhat between
central laboratories due to small variations in FISH signal
quantification. Because the same immunohistochemically
equivocal case read by both laboratories had systematically
higher ratios at Mayo than at IEO, patients classified as
eligible to enter ALTTO from North America would
include some with lower intrinsic HER2-positive FISH
signaling who would have been classified as ineligible if
screened from the rest of world. It is unlikely that this
discordance will have a meaningful impact on trial results
given the relatively few immunohistochemically equivocal
cases for which differences in interpretation of HER2 FISH
results would yield a difference in ALTTO eligibility [8].
Information regarding estrogen receptor central testing
was communicated to trial participants from both central
testing sites. Local treatment with estrogen receptor modu-
lating therapies was not specified in the trial and was deter-
mined by locally treating physicians. Whether local and
Fig. 2 HER2 FISH ratios for 23 local HER2 IHC equivocal cases
comparing Mayo and IEO in phase 3 of this ring study. All 15
amplified Mayo cases have higher FISH ratios than the IEO values
490 Breast Cancer Res Treat (2014) 143:485–492
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central discordances in ER testing would change the utili-
zation of endocrine therapy locally is not known. With
respect to ER status, more rest-of-world cases will be clas-
sified as centrally ER positive and thus may receive adjuvant
endocrine therapy which would not have been given based on
local ER-negative results. If the locally ER-negative, but
centrally ER-positive disease is in fact responsive to endo-
crine therapy, better overall results might be achieved.
Some evidence regarding the validity of IEO central
review of ER status comes from the BIG 1-98 trial [2].
Postmenopausal women with locally assessed steroid hor-
mone receptor-positive disease were enrolled. Of 3,610
cases evaluated, 94 were found by the central IEO labo-
ratory to have steroid hormone receptor-negative disease.
The subsequent disease course of these 94 patients pre-
cisely followed the natural course expected for ER-nega-
tive breast cancer—rapid early recurrence in a proportion
of patients followed by a plateau and long-term disease
freedom by many (Ref. 2, Fig 2C). Furthermore, cases with
central ER staining in 1–9 % of cells (using the single
epitope 1D5 antibody) had a disease-free survival better
than those with central ER-absent disease (no ER expres-
sion in any cells) (Ref. 2. Fig 3A).
An important side effect of the pre-randomization cen-
tral laboratory review of HER2 and ER conducted prior to
initiation of our ring study was that discordance between
central and local laboratories could be identified. ALTTO
enrollment from Germany was substantial, and it was noted
that the discordance rate for HER2 assessment from Ger-
many was slightly higher than the mean discordance rate
for all rest-of-world cases. Drs. Jackisch and Untch, Ger-
man ALTTO principal investigators, organized a meeting
of the officers of the German Society of Pathologists spe-
cifically to discuss the discordance rate. Dr. Viale provided
discordance data for each of the 192 German centers. Some
(10) high-volume laboratories in Germany were identified
as having a high discordance rate (up to 50 %), which
substantially increased the discordance rate for Germany.
Initiatives were undertaken by the German Society of
Pathologists to address the issue with the relevant centers
(see Supplementary Appendix E), and the concordance
between local German assessment and central IEO
assessment for both HER2 and ER improved substantially.
Perhaps, the most important contribution of the central
review initiative is that patients are now benefiting from
high-quality biological determination of the characteristics
of their tumor. This is particularly critical for HER2 and
ER as these two biomarkers are used to directly determine
the type of adjuvant therapy to be used.
ASCO/CAP guidelines are available to guide HER2 and
ER determination [3, 4], and proficiency testing is also
required for every laboratory that provides information for
breast cancer biomarkers. A re-evaluation of HER2
guidelines for positivity is now available [9]. It remains to
be seen whether the treatment guided by local determina-
tions leads to worse outcomes than the treatment guided by
central review. In fact, some evidence suggests that trast-
uzumab is effective for patients with centrally determined
HER2-negative disease, which was locally determined to
be HER2 positive [8, 10]. The degree of endocrine
responsiveness is unknown for that subset of tumors that
are locally ER negative but centrally ER positive based on
the newer dual antibody.
In this multinational combined collaborative group trial,
we can be assured that the patients enrolled in the trial bear
disease with the HER2 target as confirmed by central
testing. Excellent concordance in testing for trial eligibility
was obtained between central confirming laboratories using
identical methods and positivity criteria. Minor differences
in HER2 immunohistochemical quantification and FISH
amplification between central laboratories were detected in
a selected small population; standardization of these types
of morphological parameters is an area of intense explo-
ration. Differences in centrally confirmed ER IHC status
based on antibody choice were detected. A recommenda-
tion for future clinical trials involving multiple collabora-
tive groups is that the validated hormonal receptor antibody
should be specified and that central testing should be per-
formed to determine trial eligibility. Given the absence of
analytical standards in breast marker immunohistochemical
and in situ hybridization methods, similar ring study
comparisons between confirming collaborative laboratories
are encouraged in the context of clinical trials.
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